<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00607763</url>
  </required_header>
  <id_info>
    <org_study_id>9463-CL-2102</org_study_id>
    <nct_id>NCT00607763</nct_id>
  </id_info>
  <brief_title>Study of Mycamine® in Infants and Toddlers With Fungal Infections to Evaluate Safety and Blood Levels of the Drug</brief_title>
  <official_title>A Phase 1, Open-Label Study Of The Safety And Pharmacokinetics Of Repeated-Dose Micafungin (FK463) In Infants And Toddlers (≥4 Months TO &lt; 24 Months Of Age) With Esophageal Candidiasis Or Other Invasive Candidiasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Infants and toddlers with fungal infections will receive 10 to 14 days of treatment with an
      antifungal drug. Safety and drug blood levels will be assessed
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multicenter, open-label, repeat-dose study. Subjects will receive
      treatment with intravenous micafungin for 10 to 14 days (per investigator clinical judgment)
      at a daily dose of 4.5 mg/kg (determined by the subject's weight at baseline). Serial blood
      samples for assessment of pharmacokinetics will be collected.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of Micafungin pharmacokinetics</measure>
    <time_frame>10 - 14 Days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess safety and tolerability of micafungin by adverse events, vital signs, hematology and chemistry laboratory tests, ECGs and physical evaluation</measure>
    <time_frame>Day 1 to End of Study</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Invasive Candidiasis</condition>
  <condition>Esophageal Candidiasis</condition>
  <condition>Oropharyngeal Candidiasis</condition>
  <condition>Candidemia</condition>
  <arm_group>
    <arm_group_label>1. Micafungin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Micafungin (Mycamine)</intervention_name>
    <description>IV</description>
    <arm_group_label>1. Micafungin</arm_group_label>
    <other_name>FK463</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is ≥4 months to &lt; 24 months

          2. Subject has suspected, proven or probable candidiasis, candidemia or other invasive
             candidiasis

          3. Subject has sufficient venous access to permit administration of study medication,
             collection of pharmacokinetic samples, and monitoring of laboratory safety variables

        Exclusion Criteria:

          1. Subject has evidence of significant liver disease, as defined by aspartate
             transaminase (AST), alanine transaminase (ALT), bilirubin or alkaline phosphatase &gt; 5
             times the upper limit of normal (ULN)

          2. Subject has a concomitant medical condition that in the opinion of the investigator
             and/or medical monitor precludes enrollment into the study

          3. Subject has a history of anaphylaxis, hypersensitivity, or any serious reaction to the
             echinocandin class of antifungals

          4. Subject has received treatment with an echinocandin within one week prior to first
             dosing

          5. Subject status is unstable and subject is unlikely to complete all study required
             procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Months</minimum_age>
    <maximum_age>23 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Central Contact</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Global Development</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.clinicaltrials.jp/user/ctrSearch_e.jsp</url>
    <description>Link to Results on JAPIC - enter 140540 in the JapicCTI-RNo. field</description>
  </link>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2008</study_first_submitted>
  <study_first_submitted_qc>January 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2008</study_first_posted>
  <last_update_submitted>August 19, 2014</last_update_submitted>
  <last_update_submitted_qc>August 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antifungal</keyword>
  <keyword>Echinocandin</keyword>
  <keyword>Candidiasis</keyword>
  <keyword>Micafungin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candidiasis</mesh_term>
    <mesh_term>Candidemia</mesh_term>
    <mesh_term>Candidiasis, Invasive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Micafungin</mesh_term>
    <mesh_term>Echinocandins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

